|
|
|
21 Apr 2006 |
Æterna Zentaris Gains Market Approval for Cetrotide® (cetrorelix) in Japan for In Vitro Fertilization
|
|
21 Apr 2006 |
Camurus starts phase I clinical trial with CAM2029 – a new long-acting octreotide depot
|
|
19 Apr 2006 |
Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and Weight Loss
|
|
19 Apr 2006 |
Sandoz Receives European Commission Marketing Authorization for Omnitrope
|
|
19 Apr 2006 |
Neurochem announces eprodisate (Fibrillex™) NDA filed and granted priority review by the FDA for the treatment of AA amyloidosis
|
|
13 Apr 2006 |
MicroIslet Announces Encouraging Data From Islet Transplantation Studies in Primates
|
|
12 Apr 2006 |
Emisphere Completes Enrollment for Phase II Oral Insulin Clinical Trial
|
|
11 Apr 2006 |
European Regulatory Committee Recommends Orphan Medicinal Product Designation for Amicus Therapeutics' Amigal(TM) for Fabry Disease
|
|
11 Apr 2006 |
Depomed Data Published In Diabetes Care On Glumetza, An FDA-Approved Treatment For Type II Diabetes
|
|
09 Apr 2006 |
Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline
|
|
06 Apr 2006 |
Valera Pharmaceuticals Completes Phase III Study of Its Twelve-Month Implant for Treating Central Precocious Puberty
|
|
03 Apr 2006 |
Takeda Submits New Drug Application for Extended Release Type 2 Diabetes Medication, ACTOplus met (pioglitazone HCl and metformin HCl)
|
|
03 Apr 2006 |
European Commission Approves Genzyme's Myozyme
|
|
30 Mar 2006 |
New drug application for Galvus®, an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA
|
|
30 Mar 2006 |
NPS Updates Status of PREOS(R) NDA
|
|
29 Mar 2006 |
Arena Pharmaceuticals Provides APD356 Obesity and APD125 Insomnia Clinical Program Updates
|
|
29 Mar 2006 |
New Preclinical Data Shows Samaritan's Cardiovascular Drug Reduces Cholesterol; Cardiovascular Disease is a $15B Market Worldwide
|
|
27 Mar 2006 |
Elixir Pharmaceuticals Acquires Late-Stage Product for the Treatment of Type II Diabetes
|
|
27 Mar 2006 |
Exelixis Intiates Phase II Clinical Program for XL784
|
|
25 Mar 2006 |
Once-Weekly Exenatide LAR Clinical Study in Type 2 Diabetes Initiated
|
|
24 Mar 2006 |
Noxxon Pharma AG Announces Global Strategic Alliance With Pfizer
|
|
23 Mar 2006 |
Senesco’s Technology Increases Pancreatic Islet Cell Survivability In Animal Study
|
|
22 Mar 2006 |
Savient and FDA Agree on Phase 3 Protocol SPA; Puricase(R) (PEG-uricase) on Track to Enter Phase 3
|
|
21 Mar 2006 |
Tissera reports further encouraging results of its ongoing large animal experiments of pancreatic xenotransplantation
|
|
17 Mar 2006 |
New study shows women with osteoporosis preferred once-monthly dosing of Boniva over a once-weekly medicine
|
|
16 Mar 2006 |
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
|
|
15 Mar 2006 |
ActivX/Kyorin Begins First U.S. Phase I Study for Novel Anti-Diabetic Drug
|
|
15 Mar 2006 |
AdipoGenix Achieves Third Milestone in Collaboration with Johnson & Johnson
|
|
14 Mar 2006 |
Transition Therapeutics Acquires Exclusive License to GLP-1 for Type I Diabetes Patent Portfolio
|
|
14 Mar 2006 |
Data Analysis Showed VYTORIN® (ezetimibe/simvastatin) Significantly Reduced LDL “bad” Cholesterol and C-reactive Protein (CRP) in Patients with High Cholesterol Compared to Zocor® (simvastatin)
|
|
13 Mar 2006 |
ISIS 301012 Does Not Interact With Currently Marketed Lipid Lowering Drugs
|
|
13 Mar 2006 |
Crestor Shows Regression of Coronary Artery Disease in a Major Clinical Study
|
|
11 Mar 2006 |
NPS Receives Approvable Letter for PREOS NDA
|
|
09 Mar 2006 |
Indevus Announces FDA Acceptance of IND for NEBIDO(R); Company to Commence Pharmacokinetic Trial in Men with Hypogonadism
|
|
08 Mar 2006 |
Emisphere Announces Oral PTH License Agreement
|
|
08 Mar 2006 |
Generex Biotechnology Announces Positive Preliminary Results In A Long-Term Clinical Trial Of Generex Oral-Lyn™ In Juvenile Patients With Type-1 Diabetes Mellitus (Dm)
|
|
08 Mar 2006 |
Diabetica Announces A Development Licence For Gip Agonist Antidiabetic Therapeutics
|
|
07 Mar 2006 |
Titan Initiates Controlled Phase II Clinical Study of DITPA in the Treatment of Elevated Cholesterol Levels
|
|
07 Mar 2006 |
Novo Nordisk reinitiates phase 3 programme for inhalable insulin project
|
|
06 Mar 2006 |
Point Therapeutics' Diabetes Program Presented at Keystone Symposium; PT-630 Demonstrates Improvement of Glucose Regulation and Metabolic Parameters Associated With Progression of Type 2 Diabetes
|
|
06 Mar 2006 |
MannKind Initiates Two U.S. Pivotal Phase 3 Studies of Inhaled Technosphere(R) Insulin
|
|
03 Mar 2006 |
Generex Biotechnology Completes Positive Pre-NDS Meeting With Health Canada for Generex Oral-lyn(TM)
|
|
02 Mar 2006 |
Nastech Pharmaceutical Company Reacquires PYY3-36 Nasal Spray for Treatment of Obesity and Will Advance Its Clinical Development
|
|
02 Mar 2006 |
Randomized Trial Shows Ganite® Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
|
|
02 Mar 2006 |
Supplemental New Drug Application for BYETTA Submitted to FDA for Use With TZDs
|
|
01 Mar 2006 |
Liponex Receives Approval to Initiate CRD5 Clinical Trial and Updates Trial Schedule
|
|
27 Feb 2006 |
ConjuChem to Initiate Phase I/II Clinical Study of PC-DAC(TM): Exendin-4 for Type 2 Diabetes
|
|
25 Feb 2006 |
Novartis receives ''approvable letter'' from the FDA for zoledronic acid 5 mg in the treatment of Paget's disease of the bone
|
|
24 Feb 2006 |
Glenmark’s anti-diabetic, DPP-IV inhibitor, GRC 8200 successfully completes Phase I
|
|
24 Feb 2006 |
BioPartners Announces CHMP Positive Opinion for its Biosimilar Recombinant Human Growth Hormone - Valtropin™
|
| |
|
Results 951 - 1000 of 1041 |
